https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-08-29_um_06.18.31.png539982Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-08-28 13:23:192019-08-28 13:23:19Immatics and Celgene enter $1.5bn deal
US company Freenome will use its multiomics platform to develop response biomarkers to ADC Therapeutics’ Phase II antibody drug conjugate (ADC) ADCT-402.
GlaxoSmithKline plc announced belantamab mafodotin (GSK2857916) met the primary endpoint of overall response rate (ORR) in a pivotal Phase II trial in treatment-refractive multiple myeloma.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-08-26_um_09.00.11.png292693Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-08-26 08:00:122019-08-26 08:00:12GSK reaches endpoint in pivotal blood cancer study
Researchers from Paul Scherrer Institute in Villingen, Switzerland, and Hoffmann La-Roche AG report in Cell they have solved the structure of a target relevant in metastasis.
An antibody therapy that targets red blood cells (RBCs) unexpectedly showed anti-inflammatory effects and rapidly reversed rheumatoid arthritis and prevented lung injury in mouse models.
Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action to treat community-acquired bacterial pneumonia.
Zurich-based ADC maker Araris Biotech AG announced the closing of an oversubscribed seed financing round of CHF2.5m with Redalpine, Schroder Adveq and VI Partners contibuting.
Iteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.
Although it has only been shown to provide partial protection, the first-ever malaria vaccine is in testing in Africa – and there are many more hopefuls in the pipeline. Will we soon eradicate one of the most deadly pathogens in human history?
https://european-biotechnology.com/wp-content/uploads/2024/04/ebcom_2019_malariasdoom.png5631000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-08-19 15:13:052024-04-02 16:20:41The Dawn of Malaria’s Doom
Immatics and Celgene enter $1.5bn deal
Latest NewsCelgene will pay $75m upfront to get an option on three cancer programmes developed by Immatics Biotechnologies.
Microbial feed company Unibio raises US$15m
Latest NewsDanish microbiology specialist Unibio International plc had completed a US$15m financing round led by West Hill Capital.
ADC Therapeutics and Freenome enter biomarker collaboration
Latest NewsUS company Freenome will use its multiomics platform to develop response biomarkers to ADC Therapeutics’ Phase II antibody drug conjugate (ADC) ADCT-402.
GSK reaches endpoint in pivotal blood cancer study
Latest NewsGlaxoSmithKline plc announced belantamab mafodotin (GSK2857916) met the primary endpoint of overall response rate (ORR) in a pivotal Phase II trial in treatment-refractive multiple myeloma.
Swiss researchers report on metastasis switch
Latest NewsResearchers from Paul Scherrer Institute in Villingen, Switzerland, and Hoffmann La-Roche AG report in Cell they have solved the structure of a target relevant in metastasis.
Preclinical antibody stops rheumatoid arthritis
Latest NewsAn antibody therapy that targets red blood cells (RBCs) unexpectedly showed anti-inflammatory effects and rapidly reversed rheumatoid arthritis and prevented lung injury in mouse models.
Nabriva receives FDA approval for novel antibiotics
Latest NewsAraris Biotech AG kicks-off with CHF2.5m seed financing
Latest NewsZurich-based ADC maker Araris Biotech AG announced the closing of an oversubscribed seed financing round of CHF2.5m with Redalpine, Schroder Adveq and VI Partners contibuting.
Matthew Call joins Iteos as COO
AppointmentsIteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.
The Dawn of Malaria’s Doom
BackgroundAlthough it has only been shown to provide partial protection, the first-ever malaria vaccine is in testing in Africa – and there are many more hopefuls in the pipeline. Will we soon eradicate one of the most deadly pathogens in human history?